58.60 0.00 (0.00%)
After hours: 4:27PM EST
|Bid||56.55 x 400|
|Ask||67.25 x 100|
|Day's Range||56.58 - 58.88|
|52 Week Range||46.43 - 71.22|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 25, 2018 - Apr 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||61.33|
What Should Vanda Pharmaceuticals Investors Be Watching in 2018? Vanda Pharmaceuticals (VNDA) is a biopharmaceutical company with a focus on developing and commercializing innovative therapies. Vanda Pharmaceuticals has adopted a five-pronged business strategy with a goal of becoming a leading global biopharmaceutical company.
IN THE NEWS Among thematic exchange-traded funds, two of the most popular focus on the artificial intelligence and robotics investment themes. At least one ETF issuer thinks there's room for another artificial ...
Alkermes PLC (NASDAQ:ALKS) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
Stock Monitor: Alkermes Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 16, 2018 / Active-Investors.com has just released a free research report on Valeant Pharmaceuticals International, Inc. ...
Alkermes (ALKS) tops earnings and sales estimates in the fourth quarter of 2017 on the back of strong growth of Vivitrol and Aristada. The company provided a decent outlook for 2018.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
The Dublin-based company said it had a loss of 6 cents per share. Earnings, adjusted for pretax expenses and stock option expense, were 31 cents per share. The results surpassed Wall Street expectations. ...
Investors need to pay close attention to Alkermes (ALKS) stock based on the movements in the options market lately.
DUBLIN, Feb. 14, 2018 /PRNewswire/ -- Alkermes plc (ALKS) today announced the appointment of Shane Cooke to Alkermes' Board of Directors, effective March 30, 2018. The election to the Board follows Mr. Cooke's notification of his plans to retire from Alkermes at the end of March 2018. The company intends to hire a successor.
-- Record Revenues of $903.4 Million , GAAP Loss Per Share of $1.03 and Non-GAAP Diluted Earnings Per Share of $0.17 Reported for 2017 -- -- 2017 Net Sales of Proprietary Products Grew by 42% Year-Over-Year ...
NEW YORK, NY / ACCESSWIRE / February 14, 2018 / Alkermes Plc (NASDAQ: ALKS ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 14, 2018, at 8:30 AM Eastern Time. ...
Alkermes (ALKS) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
DUBLIN , Feb. 7, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. GMT ) on Wednesday, Feb. 14, 2018 , to discuss the company's ...
Alkermes Plc (NASDAQ:ALKS) was an end of the week mover in the biotechnology space but the action wasn’t driven by what we might deem a ‘standard’ biotech input. Here’s a look at what happened, why it happened and what it means going forward. On Friday, news hit press from Bloomberg reporting that Nektar Therapeutics (NASDAQ:NKTR) was considering […] The post Here’s Why Alkermes Plc Is Moving Now appeared first on Market Exclusive.